Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 101 entries
Sorted by: Best Match Show Resources per page
Self referral to consultants.

British medical journal (Clinical research ed.)

Michael G, Musgrave M, Bard V, Thwaites S, Beney J, Sumners S, Krasner D, Wyndham M.
PMID: 3126933
Br Med J (Clin Res Ed). 1988 Feb 27;296(6622):640. doi: 10.1136/bmj.296.6622.640.
Free PMC Article

No abstract available.

Cite
Michael G, Musgrave M, Bard V, et al. Self referral to consultants. Br Med J (Clin Res Ed). 1988;296(6622):640doi: 10.1136/bmj.296.6622.640.
Michael, G., Musgrave, M., Bard, V., Thwaites, S., Beney, J., Sumners, S., Krasner, D., & Wyndham, M. (1988). Self referral to consultants. British medical journal (Clinical research ed.), 296(6622), 640. https://doi.org/10.1136/bmj.296.6622.640
Michael, G, et al. "Self referral to consultants." British medical journal (Clinical research ed.) vol. 296,6622 (1988): 640. doi: https://doi.org/10.1136/bmj.296.6622.640
Michael G, Musgrave M, Bard V, Thwaites S, Beney J, Sumners S, Krasner D, Wyndham M. Self referral to consultants. Br Med J (Clin Res Ed). 1988 Feb 27;296(6622):640. doi: 10.1136/bmj.296.6622.640. PMID: 3126933; PMCID: PMC2545253.
Copy Download .nbib Format: NLM
DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation.

Frontiers in pediatrics

Dimitriades VR, Devlin V, Pittaluga S, Su HC, Holland SM, Wilson W, Dunleavy K, Shah NN, Freeman AF.
PMID: 28293550
Front Pediatr. 2017 Feb 28;5:38. doi: 10.3389/fped.2017.00038. eCollection 2017.

Dedicator of cytokinesis 8 (DOCK8) deficiency is an autosomal recessive, combined immunodeficiency within the spectrum of hyper-IgE syndromes. Epstein-Barr virus-positive lymphomatoid granulomatosis (LYG) (EBV + LYG) is a rare diagnosis and a previously unreported presentation of DOCK8 deficiency. A...

Cite
Dimitriades VR, Devlin V, Pittaluga S, et al. DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation. Front Pediatr. 2017;5:38doi: 10.3389/fped.2017.00038.
Dimitriades, V. R., Devlin, V., Pittaluga, S., Su, H. C., Holland, S. M., Wilson, W., Dunleavy, K., Shah, N. N., & Freeman, A. F. (2017). DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation. Frontiers in pediatrics, 538. https://doi.org/10.3389/fped.2017.00038
Dimitriades, Victoria R, et al. "DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation." Frontiers in pediatrics vol. 5 (2017): 38. doi: https://doi.org/10.3389/fped.2017.00038
Dimitriades VR, Devlin V, Pittaluga S, Su HC, Holland SM, Wilson W, Dunleavy K, Shah NN, Freeman AF. DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation. Front Pediatr. 2017 Feb 28;5:38. doi: 10.3389/fped.2017.00038. eCollection 2017. PMID: 28293550; PMCID: PMC5328973.
Copy Download .nbib Format: NLM
Molecular profiling of childhood cancer: Biomarkers and novel therapies.

BBA clinical

Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA.
PMID: 26675306
BBA Clin. 2014 Jun 28;1:59-77. doi: 10.1016/j.bbacli.2014.06.003. eCollection 2014 Jun.

BACKGROUND: Technological advances including high-throughput sequencing have identified numerous tumor-specific genetic changes in pediatric and adolescent cancers that can be exploited as targets for novel therapies.SCOPE OF REVIEW: This review provides a detailed overview of recent advances in the...

Cite
Saletta F, Wadham C, Ziegler DS, et al. Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin. 2014;1:59-77doi: 10.1016/j.bbacli.2014.06.003.
Saletta, F., Wadham, C., Ziegler, D. S., Marshall, G. M., Haber, M., McCowage, G., Norris, M. D., & Byrne, J. A. (2014). Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA clinical, 159-77. https://doi.org/10.1016/j.bbacli.2014.06.003
Saletta, Federica, et al. "Molecular profiling of childhood cancer: Biomarkers and novel therapies." BBA clinical vol. 1 (2014): 59-77. doi: https://doi.org/10.1016/j.bbacli.2014.06.003
Saletta F, Wadham C, Ziegler DS, Marshall GM, Haber M, McCowage G, Norris MD, Byrne JA. Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin. 2014 Jun 28;1:59-77. doi: 10.1016/j.bbacli.2014.06.003. eCollection 2014 Jun. PMID: 26675306; PMCID: PMC4633945.
Copy Download .nbib Format: NLM
EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

Wysham C, Hood RC, Warren ML, Wang T, Morwick TM, Jackson JA.
PMID: 26789342
Endocr Pract. 2016 Jun;22(6):653-65. doi: 10.4158/EP15959.OR. Epub 2016 Jan 20.

OBJECTIVE: To examine the influence of baseline U-100 insulin total daily dose (TDD) on clinical outcomes in severely insulin-resistant patients with inadequately controlled type 2 diabetes treated with human regular U-500 insulin (U-500R) from the perspective of current dosing...

Cite
Wysham C, Hood RC, Warren ML, et al. EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2016;22(6):653-65doi: 10.4158/EP15959.OR.
Wysham, C., Hood, R. C., Warren, M. L., Wang, T., Morwick, T. M., & Jackson, J. A. (2016). EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 22(6), 653-65. https://doi.org/10.4158/EP15959.OR
Wysham, Carol, et al. "EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES." Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists vol. 22,6 (2016): 653-65. doi: https://doi.org/10.4158/EP15959.OR
Wysham C, Hood RC, Warren ML, Wang T, Morwick TM, Jackson JA. EFFECT OF TOTAL DAILY DOSE ON EFFICACY, DOSING, AND SAFETY OF 2 DOSE TITRATION REGIMENS OF HUMAN REGULAR U500 INSULIN IN SEVERELY INSULIN-RESISTANT PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2016 Jun;22(6):653-65. doi: 10.4158/EP15959.OR. Epub 2016 Jan 20. PMID: 26789342.
Copy Download .nbib Format: NLM
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.

Leukemia & lymphoma

Williams ME, Connors JM, Dreyling MH, Gascoyne RD, Kahl BS, Leonard JP, Press OW, Wilson WH.
PMID: 21133727
Leuk Lymphoma. 2011 Jan;52(1):24-33. doi: 10.3109/10428194.2010.532893. Epub 2010 Dec 06.

Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma typically characterized by cyclin D1 overexpression as result of the t(11;14) translocation. MCL is biologically and clinically heterogeneous and frequently involves extranodal dissemination. Although MCL is incurable with current...

Cite
Williams ME, Connors JM, Dreyling MH, et al. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2010;52(1):24-33doi: 10.3109/10428194.2010.532893.
Williams, M. E., Connors, J. M., Dreyling, M. H., Gascoyne, R. D., Kahl, B. S., Leonard, J. P., Press, O. W., & Wilson, W. H. (2011). Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leukemia & lymphoma, 52(1), 24-33. https://doi.org/10.3109/10428194.2010.532893
Williams, Michael E, et al. "Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop." Leukemia & lymphoma vol. 52,1 (2011): 24-33. doi: https://doi.org/10.3109/10428194.2010.532893
Williams ME, Connors JM, Dreyling MH, Gascoyne RD, Kahl BS, Leonard JP, Press OW, Wilson WH. Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma. 2011 Jan;52(1):24-33. doi: 10.3109/10428194.2010.532893. Epub 2010 Dec 06. PMID: 21133727; PMCID: PMC7357185.
Copy Download .nbib Format: NLM
A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice.

Hereditary cancer in clinical practice

Ferris M, Easton DF, Doherty RJ, Briggs BH, Newman M, Saraf IM, Scambler S, Wagman L, Wyndham MT, Ward A, Eeles RA.
PMID: 19725992
Hered Cancer Clin Pract. 2007 Sep 15;5(3):157-60. doi: 10.1186/1897-4287-5-3-157.

OBJECTIVES: To conduct a pilot population-based study within a general practice catchment area to determine whether the incidence of breast cancer was increased in the Ashkenazi population.DESIGN: Population-based cohort study.SETTING: A single general practice catchment area in North London.PARTICIPANTS:...

Cite
Ferris M, Easton DF, Doherty RJ, et al. A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice. Hered Cancer Clin Pract. 2007;5(3):157-60doi: 10.1186/1897-4287-5-3-157.
Ferris, M., Easton, D. F., Doherty, R. J., Briggs, B. H., Newman, M., Saraf, I. M., Scambler, S., Wagman, L., Wyndham, M. T., Ward, A., & Eeles, R. A. (2007). A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice. Hereditary cancer in clinical practice, 5(3), 157-60. https://doi.org/10.1186/1897-4287-5-3-157
Ferris, Michelle, et al. "A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice." Hereditary cancer in clinical practice vol. 5,3 (2007): 157-60. doi: https://doi.org/10.1186/1897-4287-5-3-157
Ferris M, Easton DF, Doherty RJ, Briggs BH, Newman M, Saraf IM, Scambler S, Wagman L, Wyndham MT, Ward A, Eeles RA. A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice. Hered Cancer Clin Pract. 2007 Sep 15;5(3):157-60. doi: 10.1186/1897-4287-5-3-157. PMID: 19725992; PMCID: PMC2736988.
Copy Download .nbib Format: NLM
Heterotrophic potentials and hydrocarbon biodegradation potentials of sediment microorganisms within the athabasca oil sands deposit.

Applied and environmental microbiology

Wyndham RC, Costerton JW.
PMID: 16345737
Appl Environ Microbiol. 1981 Mar;41(3):783-90. doi: 10.1128/aem.41.3.783-790.1981.

Techniques for the enumeration and the determination of the potential activity of disturbed sediment mixed populations at control sites and sites within the Athabasca oil sands formation were applied to August and December samples. These techniques included the determination...

Cite
Wyndham RC, Costerton JW. Heterotrophic potentials and hydrocarbon biodegradation potentials of sediment microorganisms within the athabasca oil sands deposit. Appl Environ Microbiol. 1981;41(3):783-90doi: 10.1128/aem.41.3.783-790.1981.
Wyndham, R. C., & Costerton, J. W. (1981). Heterotrophic potentials and hydrocarbon biodegradation potentials of sediment microorganisms within the athabasca oil sands deposit. Applied and environmental microbiology, 41(3), 783-90. https://doi.org/10.1128/aem.41.3.783-790.1981
Wyndham, R C, and Costerton, J W. "Heterotrophic potentials and hydrocarbon biodegradation potentials of sediment microorganisms within the athabasca oil sands deposit." Applied and environmental microbiology vol. 41,3 (1981): 783-90. doi: https://doi.org/10.1128/aem.41.3.783-790.1981
Wyndham RC, Costerton JW. Heterotrophic potentials and hydrocarbon biodegradation potentials of sediment microorganisms within the athabasca oil sands deposit. Appl Environ Microbiol. 1981 Mar;41(3):783-90. doi: 10.1128/aem.41.3.783-790.1981. PMID: 16345737; PMCID: PMC243775.
Copy Download .nbib Format: NLM
Direct conversion of methane to higher hydrocarbons using AlBr3-HBr superacid catalyst.

Chemical communications (Cambridge, England)

Vasireddy S, Ganguly S, Sauer J, Cook W, Spivey JJ.
PMID: 21085725
Chem Commun (Camb). 2011 Jan 14;47(2):785-7. doi: 10.1039/c0cc01886d. Epub 2010 Nov 17.

The direct gas phase catalytic oligomerization of methane at temperatures ≤673 K has been demonstrated using AlBr(3)-HBr superacid. The reaction produces C(2)+ hydrocarbons and hydrogen in a single step at 1 atm in a continuous flow reactor at a...

Cite
Vasireddy S, Ganguly S, Sauer J, et al. Direct conversion of methane to higher hydrocarbons using AlBr3-HBr superacid catalyst. Chem Commun (Camb). 2010;47(2):785-7doi: 10.1039/c0cc01886d.
Vasireddy, S., Ganguly, S., Sauer, J., Cook, W., & Spivey, J. J. (2011). Direct conversion of methane to higher hydrocarbons using AlBr3-HBr superacid catalyst. Chemical communications (Cambridge, England), 47(2), 785-7. https://doi.org/10.1039/c0cc01886d
Vasireddy, Sivakumar, et al. "Direct conversion of methane to higher hydrocarbons using AlBr3-HBr superacid catalyst." Chemical communications (Cambridge, England) vol. 47,2 (2011): 785-7. doi: https://doi.org/10.1039/c0cc01886d
Vasireddy S, Ganguly S, Sauer J, Cook W, Spivey JJ. Direct conversion of methane to higher hydrocarbons using AlBr3-HBr superacid catalyst. Chem Commun (Camb). 2011 Jan 14;47(2):785-7. doi: 10.1039/c0cc01886d. Epub 2010 Nov 17. PMID: 21085725.
Copy Download .nbib Format: NLM
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma.

Therapeutic advances in hematology

Dunleavy K, Grant C, Wilson WH.
PMID: 23610613
Ther Adv Hematol. 2013 Feb;4(1):43-57. doi: 10.1177/2040620712464508.

While diffuse large B-cell lymphoma (DLBCL) was once considered to be a single disease entity, recent biological insights have demonstrated that it can be divided up into at least three molecular subtypes. Gene expression profiling has revealed that DLBCL...

Cite
Dunleavy K, Grant C, Wilson WH. Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. Ther Adv Hematol. 2013;4(1):43-57doi: 10.1177/2040620712464508.
Dunleavy, K., Grant, C., & Wilson, W. H. (2013). Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. Therapeutic advances in hematology, 4(1), 43-57. https://doi.org/10.1177/2040620712464508
Dunleavy, Kieron, et al. "Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma." Therapeutic advances in hematology vol. 4,1 (2013): 43-57. doi: https://doi.org/10.1177/2040620712464508
Dunleavy K, Grant C, Wilson WH. Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. Ther Adv Hematol. 2013 Feb;4(1):43-57. doi: 10.1177/2040620712464508. PMID: 23610613; PMCID: PMC3629761.
Copy Download .nbib Format: NLM
Detection of the .

Frontiers in oncology

Zorofchian S, Lu G, Zhu JJ, Duose DY, Windham J, Esquenazi Y, Ballester LY.
PMID: 30294590
Front Oncol. 2018 Sep 20;8:382. doi: 10.3389/fonc.2018.00382. eCollection 2018.

Primary Central Nervous System Lymphoma (PCNSL) and Metastatic (or Secondary) Central Nervous System Lymphoma (MCNSL) are rare central nervous system (CNS) malignancies that exhibit aggressive clinical behavior and have a poor prognosis. The majority of CNS lymphomas are histologically...

Cite
Zorofchian S, Lu G, Zhu JJ, et al. Detection of the . Front Oncol. 2018;8:382doi: 10.3389/fonc.2018.00382.
Zorofchian, S., Lu, G., Zhu, J. J., Duose, D. Y., Windham, J., Esquenazi, Y., & Ballester, L. Y. (2018). Detection of the . Frontiers in oncology, 8382. https://doi.org/10.3389/fonc.2018.00382
Zorofchian, Soheil, et al. "Detection of the ." Frontiers in oncology vol. 8 (2018): 382. doi: https://doi.org/10.3389/fonc.2018.00382
Zorofchian S, Lu G, Zhu JJ, Duose DY, Windham J, Esquenazi Y, Ballester LY. Detection of the . Front Oncol. 2018 Sep 20;8:382. doi: 10.3389/fonc.2018.00382. eCollection 2018. PMID: 30294590; PMCID: PMC6158312.
Copy Download .nbib Format: NLM
CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?.

The New England journal of medicine

Roschewski M, Longo DL, Wilson WH.
PMID: 34904797
N Engl J Med. 2021 Dec 14; doi: 10.1056/NEJMe2118899. Epub 2021 Dec 14.

No abstract available.

Cite
Roschewski M, Longo DL, Wilson WH. CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?. N Engl J Med. 2021;doi: 10.1056/NEJMe2118899.
Roschewski, M., Longo, D. L., & Wilson, W. H. (2021). CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?. The New England journal of medicine, . https://doi.org/10.1056/NEJMe2118899
Roschewski, Mark, et al. "CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?." The New England journal of medicine vol. (2021). doi: https://doi.org/10.1056/NEJMe2118899
Roschewski M, Longo DL, Wilson WH. CAR T-Cell Therapy for Large B-Cell Lymphoma - Who, When, and How?. N Engl J Med. 2021 Dec 14; doi: 10.1056/NEJMe2118899. Epub 2021 Dec 14. PMID: 34904797.
Copy Download .nbib Format: NLM
Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure.

Leukemia & lymphoma

Melani C, Wilson WH.
PMID: 34763592
Leuk Lymphoma. 2021 Nov 11;1-3. doi: 10.1080/10428194.2021.2002323. Epub 2021 Nov 11.

No abstract available.

Cite
Melani C, Wilson WH. Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure. Leuk Lymphoma. 2021;1-3doi: 10.1080/10428194.2021.2002323.
Melani, C., & Wilson, W. H. (2021). Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure. Leukemia & lymphoma, 1-3. https://doi.org/10.1080/10428194.2021.2002323
Melani, Christopher, and Wilson, Wyndham H. "Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure." Leukemia & lymphoma vol. (2021): 1-3. doi: https://doi.org/10.1080/10428194.2021.2002323
Melani C, Wilson WH. Front-Line treatment of diffuse large B-Cell lymphoma in patients with cardiovascular comorbidities; omission of anthracycline reduces cure. Leuk Lymphoma. 2021 Nov 11;1-3. doi: 10.1080/10428194.2021.2002323. Epub 2021 Nov 11. PMID: 34763592.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 101 entries